Aarti Pharmalabs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹610 Cr +45.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AP

Aarti Pharmalabs Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹583Cr
+3.4% YoY
+35% QoQ
Net profit
₹61Cr
−30.7% YoY
+27.1% QoQ
Margin
19%
−7 pp YoY
−5 pp QoQ
Price₹817
Market cap₹6.2K Cr
P/E35.0

The short version

The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.

From Aarti Pharmalabs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years.
  • CDMO vertical is expected to grow at a robust 40%-50% next year (FY2027), driving higher value growth.
  • Xanthine segment aims to achieve around Rs.1,000 Crores revenue in FY2027, showing strong volume and value growth.
  • API/intermediates segment is expected to surpass FY2025 revenue levels (approx. Rs.700-770 Crores) in FY2027, recovering from previous degrowth due to inventory and price erosion issues.
  • Ramp-up of new capacities (Atali and Xanthine expansion) to contribute meaningfully to revenues and EBITDA starting from FY2027 Q2 onwards.

2 more points from Aarti Pharmalabs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.
  • Capex for dedicated manufacturing block is included but the exact amount is still being finalized.
  • Atali plant expansion to continue with one new block per year, focusing more on brownfield expansions going forward to reduce capex intensity and speed up ramp-up.
  • Xanthine derivative capacity to increase from 6,000 to 9,000 metric tons per annum by gradual ramp-up next few quarters.
  • Steroid and anticancer blocks at Tarapur Unit-4 are undergoing debottlenecking and brownfield expansions in FY2027.

2 more points from Aarti Pharmalabs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company currently has 21 active CDMO customers, a number steady over the last five quarters.
  • Engagements with these customers are ongoing for newer projects, indicating pipeline development.
  • In 2025, there was a slowdown in inquiries due to global uncertainties, but the situation has stabilized with increasing inquiries now.
  • The management mentions having long-term and near-term understandings with customers regarding volumes for new capacities, indicating good visibility on future orders.
  • Capex decisions for custom-built facilities are based on sensible forecasts from customers.

2 more points from Aarti Pharmalabs Ltd's call on order book

Create a free account to keep reading this call

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aarti Pharmalabs Ltd Q4 FY26 results — key figures

Aarti Pharmalabs Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue583564+3.4%432+35%
Operating profit (EBITDA)113146-22.6%102+10.8%
Operating margin19%26%-7 pp24%-5 pp
Profit before tax82115-28.7%63+30.2%
Net profit (PAT)6188-30.7%48+27.1%
EPS (₹)6.749.75-30.9%5.29+27.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q4 FY26 results?

The company targets a long-term revenue growth of 15% to 18% annually over the next 3-4 years. Revenue growth guidance of 15%-18% CAGR over the next 3-4 years.

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Rs.400 Crores capex planned for FY2027, spread across four primary areas: completion of Xanthine expansion, Atali Phase 1 capitalization and start of Phase 2, debottlenecking projects, and normal replacement capex.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.